Thursday, July 15, 2021 10:48:12 AM
Cassava Sciences (NASDAQ:SAVA) was downgraded by equities researchers at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research report issued on Thursday, The Fly reports.
SAVA has been the subject of several other reports. B. Riley increased their target price on shares of Cassava Sciences from $78.00 to $111.00 and gave the company a "buy" rating in a research note on Wednesday, June 23rd. Zacks Investment Research lowered shares of Cassava Sciences from a "hold" rating to a "sell" rating in a research note on Wednesday, June 23rd. Finally, Jonestrading reissued a "buy" rating on shares of Cassava Sciences in a research note on Tuesday, March 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of "Buy" and an average price target of $53.20.
Cassava Sciences stock opened at $97.00 on Thursday. The company has a 50 day moving average of $68.42. The company has a market capitalization of $3.88 billion, a PE ratio of -334.47 and a beta of 1.09. Cassava Sciences has a 12-month low of $2.78 and a 12-month high of $117.54.
Cassava Sciences (NASDAQ:SAVA) last posted its quarterly earnings data on Tuesday, April 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Analysts expect that Cassava Sciences will post 0.24 earnings per share for the current year.
Several large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of Cassava Sciences by 22.0% in the 1st quarter. BlackRock Inc. now owns 2,404,922 shares of the company's stock valued at $108,102,000 after acquiring an additional 434,153 shares in the last quarter. Caas Capital Management LP purchased a new stake in shares of Cassava Sciences in the 4th quarter valued at approximately $4,687,000. Nuveen Asset Management LLC lifted its position in shares of Cassava Sciences by 569.1% in the 4th quarter.
Nuveen Asset Management LLC now owns 611,863 shares of the company's stock valued at $2,032,000 after acquiring an additional 520,414 shares in the last quarter. Geode Capital Management LLC lifted its position in Cassava Sciences by 22.7% in the 1st quarter. Geode Capital Management LLC now owns 561,677 shares of the company's stock worth $25,247,000 after buying an additional 103,857 shares in the last quarter. Finally, Bleichroeder LP lifted its position in Cassava Sciences by 75.9% in the 1st quarter. Bleichroeder LP now owns 500,000 shares of the company's stock worth $22,475,000 after buying an additional 215,686 shares in the last quarter. Institutional investors and hedge funds own 26.57% of the company's stock.
https://www.marketbeat.com/instant-alerts/nasdaq-sava-a-buy-or-sell-right-now-2021-07-2-3/
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM